NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 67 filers reported holding NURIX THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $350,438 | -31.3% | 44,585 | -12.7% | 0.00% | 0.0% |
| Q2 2023 | $510,099 | +18.9% | 51,061 | +5.7% | 0.00% | 0.0% |
| Q1 2023 | $429,037 | -20.5% | 48,315 | -1.7% | 0.00% | 0.0% |
| Q4 2022 | $539,788 | -12.5% | 49,161 | +3.9% | 0.00% | 0.0% |
| Q3 2022 | $617,000 | +3.0% | 47,323 | +0.2% | 0.00% | 0.0% |
| Q2 2022 | $599,000 | +40.6% | 47,246 | +55.6% | 0.00% | 0.0% |
| Q1 2022 | $426,000 | -56.4% | 30,372 | -10.1% | 0.00% | 0.0% |
| Q4 2021 | $978,000 | -2.0% | 33,799 | +1.5% | 0.00% | 0.0% |
| Q3 2021 | $998,000 | -12.9% | 33,312 | -22.9% | 0.00% | 0.0% |
| Q2 2021 | $1,146,000 | +2.0% | 43,188 | +19.6% | 0.00% | 0.0% |
| Q1 2021 | $1,123,000 | +94.0% | 36,111 | +104.9% | 0.00% | 0.0% |
| Q4 2020 | $579,000 | -1.4% | 17,620 | +4.8% | 0.00% | 0.0% |
| Q3 2020 | $587,000 | – | 16,805 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |